Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow References
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Disclaimer
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Pfeffer, M.A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Pfeffer, M.A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


The intersection between acute coronary syndrome and heart failure

M.A. Pfeffer*

Cardiovascular Division, Brigham and Women's Hospital, Boston, Massachusetts, U.S.A.

* Marc A. Pfeffer, Cardiovascular Division, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, U.S.A.

Abstract

There is a tremendous spectrum of disease severity within the diagnosis of myocardial infarction. The risk of major cardiovascular outcomes is highly related to age and concomitant medical conditions, as well as factors that characterize the extent of the myocardial infarction. Patients that develop pulmonary congestion with transient signs of heart failure and/or left ventricular dysfunction as measured by a reduced ejection fraction are generally at the high end of risk stratification. Prior studies have demonstrated that these patients derive particular benefit with the use of angiotensin-converting enzyme (ACE) inhibitors. The development of angiotensin-receptor blockers (ARBs) raises the question of whether this mode of inhibiting the renin-angiotensin system will be as good as or potentially even better than the ACE inhibitors. Unfortunately, the first major test of this concept in the Optimal Therapy in Myocardial Infarction with the Angiotensin II Antagonist Losartan (OPTIMAAL) study did not show a favourable trend for the ARB. The Valsartan in Acute Myocardial Infarction Trial (VALIANT) study is in its final phases of completion and is testing whether the use of the ARB valsartan either alone or in combination with captopril can improve survival over and above what is already achievable with the ARB. Since this patient population is at particularly high risk, even small relative improvements in clinical outcomes will have major public health implications.

Key Words: ACE inhibitor • angiotensin-receptor • blocker • heart failure • myocardial infarction • OPTIMAAL • VALIANT


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.